ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

Modern Treatment Approaches for Vasomotor and Allergic Rhinitis: Clinical Guidelines and Innovative Strategies

Otaqulov Otabek
Assistant, Department of Surgical Diseases, Central Asian Medical University, Fergana, Uzbekistan
Tokhirjon Abdunazarov
Assistant, Department of Surgical Diseases, Central Asian Medical University, Fergana, Uzbekistan
Komolidinov Bobur
Assistant, Department of Surgical Diseases, Central Asian Medical University, Fergana, Uzbekistan

Abstract

Vasomotor and allergic rhinitis are common upper airway conditions that significantly affect patients' quality of life and impose a substantial socio-economic burden. This article provides a comprehensive overview of their modern treatment strategies, based on current international guidelines. The pathogenesis, diagnostic approaches, and therapeutic options—ranging from pharmacotherapy (antihistamines, corticosteroids, antileukotrienes) to biologics and surgical methods—are thoroughly discussed. Emphasis is placed on the integration of innovative treatments such as specific immunotherapy, botulinum toxin injections, and minimally invasive surgical techniques. The review highlights evidence-based recommendations from leading organizations such as EAACI and ARIA, aiming to optimize patient outcomes through a personalized and multidisciplinary approach.

Keywords

Allergic rhinitis, Vasomotor rhinitis, Antihistamines, Nasal corticosteroids, Immunotherapy, Biologic therapy, Conchotomy, EAACI, ARIA, Rhinology, Upper airway diseases

INTRODUCTION

Vasomotor and allergic rhinitis are common upper respiratory tract disorders characterized by non-inflammatory swelling of the nasal mucosa, sneezing, nasal congestion, and rhinorrhea. According to the World Health Organization (WHO) and the European Academy of Allergy and Clinical Immunology (EAACI), allergic rhinitis affects 25–30% of the global population, while vasomotor rhinitis affects up to 10%. Based on 2022 statistics from the Ministry of Health of Uzbekistan, these pathologies account for 16–18% of ENT complaints. The complexity of these diseases lies not only in their symptoms but also in their negative socioeconomic, psychological, and quality-of-life impact.

PATHOGENESIS

Allergic Rhinitis

The pathogenesis of allergic rhinitis centers on IgE-mediated type I hypersensitivity. Upon repeated exposure to allergens, mast cells activate via high-affinity IgE receptors, releasing mediators such as histamine, tryptase, prostaglandins, and leukotrienes. These increase capillary permeability, cause mucosal swelling, and intensify rhinorrhea.

Vasomotor Rhinitis

In vasomotor rhinitis, the main factor is autonomic nervous system imbalance, with increased levels of neuropeptides like CGRP (calcitonin gene-related peptide), substance P, and VIP (vasoactive

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

intestinal peptide). These substances cause reflexive vasodilation and plasma leakage. Triggers include stress, cold air, and strong odors.

DIAGNOSIS

- Clinical symptoms: sneezing, rhinorrhea, nasal congestion, lacrimation, itching
- Rhinoscopy: pale mucosa in allergic rhinitis; hyperemic in vasomotor rhinitis
- Nasal cytology: presence of eosinophils
- Specific IgE testing (RAST, ELISA)
- CT/MRI: to rule out sinusitis or polyposis
- Rhinomanometry: assesses nasal airway patency
- Allergen provocation tests – both in vivo and in vitro

PHARMACOTHERAPY

1. **Antihistamines**
   - *Desloratadine (Aerius)* – H1-blocker, non-sedating, 5 mg/day
   - *Levocetirizine (Xyzal)* – potent H1-antagonist, 5 mg/day
2. **Nasal corticosteroids**
   - *Mometasone furoate (Nasonex)* – GR-alpha receptor agonist, anti-inflammatory
   - *Fluticasone propionate (Flixonase, Avamys)* – inhibits secretion of IL-4, IL-5, IL-13
3. **Antileukotrienes**
   - *Montelukast (Singulair)* – CysLT1 receptor blocker, effective in late-phase symptoms
4. **Biologic therapy (for severe cases)**
   - *Omalizumab (Xolair)* – binds IgE, blocks mast cell activation
   - *Dupilumab* – IL-4Rα antagonist, used in combination with asthma and allergic rhinitis

📌 According to the WAO 2022 meta-analysis, the combination of nasal corticosteroids and antihistamines reduces symptoms by up to 76%.

INNOVATIVE METHODS

- **Specific immunotherapy (SIT)** – sublingual (SLIT) or subcutaneous (SCIT); course duration: 3–5 years
- **Botulinum toxin A injection** – reduces swelling and secretion without turbinate atrophy
- **Endonasal radiofrequency / laser / cryotherapy** – minimally invasive reduction of nasal turbinates

SURGICAL TREATMENT OPTIONS

Surgical intervention is crucial in cases resistant to pharmacotherapy and immunotherapy, especially with persistent mucosal hypertrophy. The goal is to restore nasal patency, improve breathing quality, and enhance overall life quality.

1. **Submucosal or radiofrequency turbinate reduction (conchotomy)**
   - Improves airway patency by reducing tissue volume thermally or mechanically
   - *Advantages*: Preserves mucosa, minimal bleeding, short recovery
   - *Indications*: Chronic nasal obstruction, hypertrophic or medicamentous rhinitis
2. **Laser turbinate reduction**
   - Uses CO_2 or diode laser for minimally invasive tissue ablation
   - *Advantages*: Aseptic, can be done outpatient, low mucosal atrophy
3. **Ultrasound or plasma turbinate reduction**
   - Reduces turbinates using ultrasound energy or cold plasma ablation
   - *Clinical outcome*: 70–90% symptom control within 6 months

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

4. **Septoplasty or submucosal resection (septo-/septectomy)**
   - Indicated if septal deviation is present, combined with conchotomy
   - Necessary for minimizing complications and restoring airway symmetry
5. **Vasotomy**
   - Surgical interruption of vasomotor nerve fibers in inferior turbinates
   - Rarely used, but effective in severe vasomotor rhinitis cases

RECOMMENDATIONS

👉 According to ARIA and EAACI clinical guidelines, key treatment strategies include:

- Avoidance of allergen exposure
- Individualized drug selection based on symptom type
- Combination pharmacotherapy
- Continuous monitoring and treatment assessment

CONCLUSION

Effective treatment of vasomotor and allergic rhinitis requires an integrated approach that combines pharmacologic (antihistamines, steroids, antileukotrienes), pathogenetic (biologic therapy), and mechanical (surgical and immunotherapy) interventions. A balanced treatment strategy guided by EAACI and ARIA recommendations is the most effective method for reducing symptoms, improving quality of life, and preventing complications.

Key References:

- Bousquet J et al. *Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines*. Allergy, 2020
- *Global Atlas of Allergy*. EAACI, 2022
- *WAO White Book on Allergy*, 2021
- Meltzer EO, Bukstein DA. *Pharmacologic treatment of allergic rhinitis*. JACI, 2022
- Fokkens WJ et al. *EPOS 2020 guidelines for sinonasal diseases*
- Ministry of Health, Uzbekistan. *2022 National ENT Disease Statistics*
- WHO & CDC: *Allergic Disease Prevalence*, 2023 Review